Eisai licenses Nuvation lung cancer pill; Alnylam's stock dips after sales data report
Eisai licenses Nuvation lung cancer pill; Alnylam's stock dips after sales data report
Body unavailable. Use the original source.
Eisai licenses Nuvation lung cancer pill; Alnylam's stock dips after sales data report
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.